Flerie AB (publ) is increasing its ownership in Prokarium by investing £4.75 million to advance microbial immunotherapy for bladder cancer.

Target Company Information

Flerie AB (publ), a biopharmaceutical investment firm, is expanding its stake in Prokarium, an innovative immunotherapy company, through a £4.75 million investment. This funding marks the first tranche of Flerie's investment, primarily involving the conversion of loans. The financial injection aims to enhance Prokarium's ownership structure and bolster the company’s efforts in advancing its pioneering microbial immunotherapy targeting bladder cancer. Following the completion of this transaction, Prokarium's valuation is projected to decrease Flerie's net asset value by SEK 183 million in relation to its value recorded on 31 October 2025.

Industry Overview

The immunotherapy sector in the UK, particularly in the field of oncology, is rapidly evolving, driven by the demand for advanced treatment modalities. Bladder cancer remains a significant public health challenge, given the high recurrence rate associated with existing standard care treatments. Innovation in this space is crucial, as new therapies promise to enhance patient outcomes and provide alternatives to traditional methodologies.

The UK boasts a well-established biopharmaceutical landscape, characterized by a robust pipeline of investigational therapies and comprehensive clinical research facilities.